Corporate Action Today: Prakash Pipes, Nectar Lifesciences and More Turn Record Date on Dec 24, 2025

Shares of Prakash Pipes, GRM Overseas, and Nectar Lifesciences are expected to see action in today’s session as all 3 will trade ex-date on December 24, 2025, following key corporate announcements.

Prakash Pipes: Interim Dividend

Prakash Pipes has announced an interim dividend of ₹1 per share. The company has fixed December 24, 2025, as both the ex-date and record date. Investors must hold the stock before this date to be eligible for the dividend.

GRM Overseas: Bonus Issue

GRM Overseas has declared a bonus issue in the ratio of 2:1. This means shareholders will receive 2 bonus shares for every 1 share held. The record date is December 24, 2025, which is also the ex-date.

Nectar Lifesciences: Share Buyback

Nectar Lifesciences has announced a buyback of up to 3 crore equity shares, representing 13.38% of its total equity, at a price of ₹27 per share. The record date for eligibility is December 24, 2025.

Key Ex-Date Details at a Glance

• GRM Overseas – Bonus issue (2:1) – Ex-date: Dec 24, 2025
• Nectar Lifesciences – Buyback of shares – Ex-date: Dec 24, 2025
• Prakash Pipes – Interim dividend of ₹1 – Ex-date: Dec 24, 2025

Read More, GRM Overseas Bonus Issue Record Date is Tomorrow, December 24! 

Other Stocks to Watch: Rights Issues

Vineet Laboratories and Yug Decor will also be in focus as they will trade ex-date for their rights issues.

• Vineet Laboratories: Rights issue worth ₹29.96 crore at ₹30 per share
• Yug Decor: Rights issue worth ₹5.39 crore at ₹10 per share
• Record date for both: December 23, 2025

Conclusion

With multiple stocks turning ex-date this week, investors should review their portfolios carefully. Holding shares in a valid demat account before the ex-date is essential to qualify for dividends, bonus shares, or buyback benefits.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.